At Adaptive, we’re investing in the continued development of immune medicine products, which add new meaning to the stories every patient’s immune system has to tell.
1. Available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.
2. Product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The “1st Shared” and “2nd Shared” product candidates refer to the two lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to, the FDA.
3. Product candidates in development.